An ad hoc committee will plan and conduct a workshop that will use case examples to define and evaluate the perceived value of genetic and genomic technologies (both present and future) from different stakeholder perspectives, e.g. patients, providers, and payers. The workshop will feature invited presentations and discussions on this topic. The goal is to have a rigorous discussion, in which anticipated benefits and risks are considered, and to obtain information that will help advance discussions within the Roundtable membership and among other policymakers and the broader public on these issues. An individually-authored summary of the workshop will be prepared by a designated rapporteur.